Company news
PureTech Health PLC news in 2025
PureTech Health PLC's news releases, calls and decks from 2025, newest first.
PureTech Appoints Robert Lyne as Chief Executive Officer
December 18, 2025
PureTech Appoints Robert Lyne as CEO
December 18, 2025
Results of AGM on June 16, 2025 – Update Statement
December 10, 2025
Holding(s) in Company
December 10, 2025
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
December 8, 2025
PRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
December 8, 2025
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
December 5, 2025
PRTC's Gallop: Positive Initial Topline AML Data
December 5, 2025
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
November 3, 2025
PRTC: New LYT-200 AML Data + Update at ASH
November 3, 2025
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
October 22, 2025
PRTC: New IPF Data Show Benefit in Older Patients
October 22, 2025
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
September 29, 2025
PRTC: New IPF Data Show Switch Patients Stabilized
September 29, 2025
Pdmr dealing - purchase of shares
September 24, 2025
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
September 11, 2025
PRTC's Seaport Advances 2nd Candidate Into Clinic
September 11, 2025
PureTech Health plc – Half-Year Report
August 28, 2025
Half-year Report
August 28, 2025
PureTech Showcases Differentiated IPF Strategy
August 21, 2025
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
August 21, 2025
PureTech Health: Notice of Half-Yearly Results
August 18, 2025
Notice of Results
August 18, 2025
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 13, 2025
PRTC's Vedanta Announces VE202 Phase 2 Results
August 13, 2025
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
August 12, 2025
PRTC Launches Celea to Advance Ph3-Ready IPF Drug
August 12, 2025
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
July 17, 2025
PRTC’s Seaport Begins Phase 2b Study in MDD
July 17, 2025
PureTech Announces Leadership Transition
July 16, 2025
PureTech Announces Board Change
July 8, 2025
Directorate Change
July 8, 2025
PDMR Notification
July 4, 2025
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
June 26, 2025
PRTC'S Vor Announces RemeGen License & $175M PIPE
June 26, 2025
PureTech Health: Results of Annual General Meeting
June 16, 2025
Result of AGM
June 16, 2025
PureTech to Present at the Jefferies Global Healthcare Conference
May 22, 2025
PRTC to Present at Jefferies Healthcare Conference
May 22, 2025
PRTC: IPF Data Support Lung Function Stabilization
May 21, 2025
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
May 20, 2025
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
May 9, 2025
PRTC Publishes Research on Unmet IPF Patient Needs
May 9, 2025
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
May 1, 2025
PRTC To Present Ph2b IPF Results at ATS Conference
May 1, 2025
PureTech Announces Annual Results for Year Ended December 31, 2024
April 30, 2025
Final Results
April 30, 2025
PureTech Health: Notice of Results
April 23, 2025
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
April 9, 2025
PRTC Appoints Peel Hunt Joint UK Corporate Broker
April 9, 2025